Display options
Cite
Uetz-von Allmen E, Samson GPB, Purvanov V, et al. CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Front Immunol. 2021;12:702453doi: 10.3389/fimmu.2021.702453.
Uetz-von Allmen, E., Samson, G. P. B., Purvanov, V., Maeda, T., & Legler, D. F. (2021). CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Frontiers in immunology, 12702453. https://doi.org/10.3389/fimmu.2021.702453
Uetz-von Allmen, Edith, et al. "CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration." Frontiers in immunology vol. 12 (2021): 702453. doi: https://doi.org/10.3389/fimmu.2021.702453
Uetz-von Allmen E, Samson GPB, Purvanov V, Maeda T, Legler DF. CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. Front Immunol. 2021 Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453. eCollection 2021. PMID: 34603281; PMCID: PMC8482423.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453. eCollection 2021.

CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration.

Frontiers in immunology

Edith Uetz-von Allmen, Guerric P B Samson, Vladimir Purvanov, Takahiro Maeda, Daniel F Legler

Affiliations

  1. Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland.
  2. Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Bern, Switzerland.
  3. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  4. Theodor Kocher Institute, University of Bern, Bern, Switzerland.
  5. Department of Biology, University of Konstanz, Konstanz, Germany.

PMID: 34603281 PMCID: PMC8482423 DOI: 10.3389/fimmu.2021.702453

Abstract

Dendritic cells (DCs) are potent and versatile professional antigen-presenting cells and central for the induction of adaptive immunity. The ability to migrate and transport peripherally acquired antigens to draining lymph nodes for subsequent cognate T cell priming is a key feature of DCs. Consequently, DC-based immunotherapies are used to elicit tumor-antigen specific T cell responses in cancer patients. Understanding chemokine-guided DC migration is critical to explore DCs as cellular vaccines for immunotherapeutic approaches. Currently, research is hampered by the lack of appropriate human cellular model systems to effectively study spatio-temporal signaling and CCR7-driven migration of human DCs. Here, we report that the previously established human neoplastic cell line CAL-1 expresses the human DC surface antigens CD11c and HLA-DR together with co-stimulatory molecules. Importantly, if exposed for three days to GM-CSF, CAL-1 cells induce the endogenous expression of the chemokine receptor CCR7 upon encountering the clinically approved TLR7/8 agonist Resiquimod R848 and readily migrate along chemokine gradients. Further, we demonstrate that CAL-1 cells can be genetically modified to express fluorescent (GFP)-tagged reporter proteins to study and visualize signaling or can be gene-edited using CRISPR/Cas9. Hence, we herein present the human CAL-1 cell line as versatile and valuable cellular model system to effectively study human DC migration and signaling.

Copyright © 2021 Uetz-von Allmen, Samson, Purvanov, Maeda and Legler.

Keywords: CCL19; CCL21; CRISPR/Cas9 mediated CCR7 knockout ; cell migration; chemokine receptor CCR7; chemotaxis; expression of fluorescent reporter proteins; human dendritic cell line

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Front Immunol. 2020 Apr 22;11:720 - PubMed
  2. J Immunol. 2011 Dec 1;187(11):5645-52 - PubMed
  3. Immunol Lett. 2008 May 15;117(2):191-7 - PubMed
  4. Trends Immunol. 2002 Sep;23(9):445-9 - PubMed
  5. J Leukoc Biol. 2018 Aug;104(2):401-411 - PubMed
  6. Blood. 2004 Mar 1;103(5):1595-601 - PubMed
  7. J Leukoc Biol. 2018 Aug;104(2):375-389 - PubMed
  8. Nat Rev Immunol. 2017 Jan;17(1):30-48 - PubMed
  9. Cell. 2001 Aug 10;106(3):255-8 - PubMed
  10. Cell Rep. 2019 Oct 22;29(4):995-1009.e6 - PubMed
  11. J Immunol. 2004 Jun 1;172(11):6715-22 - PubMed
  12. Blood. 2005 Jul 15;106(2):444-6 - PubMed
  13. Blood. 2002 Dec 15;100(13):4512-20 - PubMed
  14. Int J Hematol. 2005 Feb;81(2):148-54 - PubMed
  15. Immunity. 2015 Jun 16;42(6):1197-211 - PubMed
  16. J Leukoc Biol. 2016 Jun;99(6):869-82 - PubMed
  17. Eur J Immunol. 2018 Jun;48(6):1074-1077 - PubMed
  18. Front Immunol. 2021 Mar 24;12:662866 - PubMed
  19. J Leukoc Biol. 2007 Nov;82(5):1106-14 - PubMed
  20. Nature. 1998 Mar 19;392(6673):245-52 - PubMed
  21. Annu Rev Immunol. 2014;32:659-702 - PubMed
  22. Annu Rev Immunol. 2002;20:621-67 - PubMed
  23. Annu Rev Immunol. 2013;31:563-604 - PubMed
  24. J Cell Biol. 1998 Oct 19;143(2):501-10 - PubMed
  25. Nat Methods. 2013 Aug;10(8):795-803 - PubMed
  26. Eur J Immunol. 1998 Sep;28(9):2760-9 - PubMed
  27. PLoS One. 2016 Apr 22;11(4):e0154094 - PubMed
  28. F1000Res. 2018 Jan 23;7:95 - PubMed
  29. Nat Commun. 2017 Apr 03;8:14830 - PubMed
  30. Front Immunol. 2019 Jan 14;9:3115 - PubMed
  31. Annu Rev Immunol. 2021 Apr 26;39:131-166 - PubMed
  32. Blood. 2009 Mar 12;113(11):2451-60 - PubMed
  33. Int J Mol Sci. 2018 Dec 04;19(12): - PubMed
  34. Nat Immunol. 2014 Jul;15(7):623-30 - PubMed
  35. Immunity. 2016 Jan 19;44(1):1-2 - PubMed
  36. Annu Rev Immunol. 2016 May 20;34:93-119 - PubMed
  37. Clin Cancer Res. 2016 Apr 15;22(8):1897-906 - PubMed
  38. Immunity. 2013 Jul 25;39(1):38-48 - PubMed
  39. EMBO J. 2002 Aug 1;21(15):4104-13 - PubMed
  40. Int J Mol Sci. 2021 Apr 16;22(8): - PubMed
  41. Curr Opin Immunol. 2018 Jun;52:74-80 - PubMed
  42. Science. 2013 Jan 18;339(6117):328-32 - PubMed
  43. Semin Cell Dev Biol. 2019 Feb;86:77-88 - PubMed
  44. Cancers (Basel). 2019 Apr 28;11(5): - PubMed
  45. Front Immunol. 2018 Aug 28;9:1949 - PubMed
  46. Blood. 2012 May 31;119(22):5191-200 - PubMed
  47. Immunity. 2016 Jan 19;44(1):59-72 - PubMed
  48. J Exp Med. 1994 Apr 1;179(4):1109-18 - PubMed
  49. J Immunol. 2006 Jan 15;176(2):966-73 - PubMed
  50. J Leukoc Biol. 2016 Jun;99(6):993-1007 - PubMed

Publication Types